as 09-18-2025 9:39am EST
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Founded: | 2013 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 77.4M | IPO Year: | 2020 |
Target Price: | $5.00 | AVG Volume (30 days): | 2.7M |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.56 | EPS Growth: | N/A |
52 Week Low/High: | $0.81 - $1.84 | Next Earning Date: | 11-06-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | PMVP | 10% Owner | Sep 10 '25 | Sell | $1.80 | 500,000 | $900,000.00 | 5,975,291 |
PMVP Breaking Stock News: Dive into PMVP Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 months ago
Simply Wall St.
4 months ago
GlobeNewswire
4 months ago
Zacks
6 months ago
GlobeNewswire
7 months ago
Simply Wall St.
7 months ago
GlobeNewswire
7 months ago
Simply Wall St.
8 months ago
The information presented on this page, "PMVP PMV Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.